Definitive Contract 75N91023C00008
Award Date
2/28/23
Potential Completion Date
12/31/24
Potential Value
$353K
Federal Agency
National Cancer Institute
Awardee
Dclk1 LLC
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Kansas City, MO 64111, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
17
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
The U.S. National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Phase I contract to Isola Therapeutics Inc., a for-profit small business, for the project "Drug Delivery by Endoesophageal Lavage (EEL) to Treat Esophageal Cancer". The $455,000 fixed-price contract has a period of performance through March 14, 2025. This award was made under the NCI's SBIR program, which aims to stimulate technological innovation, strengthen the role of small businesses in...
This is a Small Business Innovation Research (SBIR) Concept Award from the National Cancer Institute (NCI), a civilian agency, to Qana Therapeutics Inc. The $354,672 Firm Fixed Price contract is for the development of therapeutic technologies targeting ferroptosis inducers for the treatment of adrenocortical carcinoma, a rare cancer type. The contract is part of the NCI's SBIR Innovative Concept Award Program, which seeks innovative and potentially transformative technologies for the...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services. The $355,000 Firm Fixed Price contract was awarded to Insilicom LLC, a minority-owned and woman-owned small business, to develop a proof-of-concept technology for drug repurposing targeting rare cancers using a large-scale, high-quality biomedical knowledge graph. The original contract opportunity was a...
This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
This is a $300,000.00 Firm Fixed Price contract awarded by the National Cancer Institute (NCI), a civilian agency, to Chimeron Bio Corporation, a small business manufacturer, for PHASE I THERAPEUTIC AWARD: CHIMERIC NANOPARTICLE DELIVERY OF AN SARNA-BASED CANCER VACCINE FOR FAMILIAL ADENOMATOUS POLYPOSIS under the Small Business Innovation Research (SBIR) Program. The contract is set aside for small businesses. This award is associated with a pre-solicitation opportunity that sought proposals...
<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Nanoscale Corporation for the development of a rapid in vitro screening assay to detect cancer biomarkers in urine and blood. The $150,000.00 firm-fixed-price contract has a completion date of May 2, 2013. This SBIR contract is part of the NCI's efforts to support small businesses in the development of innovative cancer-related technologies.</p>
The U.S. National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Celldex Therapeutics, Inc. in the amount of $199,398.00 on September 20, 2012. The contract is for "OTHER FUNCTIONS - R & D BIOMEDICAL (BASIC RESEARCH)" and has a firm fixed price pricing type. The contract has an ultimate completion date of August 23, 2013. This SBIR Phase I award supports basic research and development activities at Celldex Therapeutics, a for-profit small...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Nomocan Pharmaceuticals LLC, a for-profit limited liability company, for $354,959. The contract is for the development of a therapeutic technology, device, or diagnostic technology to treat, detect, or diagnose pediatric cancers and rare cancers with survival rates below 50%. The contract has a firm fixed-price pricing type...
<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Phase 2 contract worth $299,920.00 to Akrivis Technologies, LLC, a minority-owned, small disadvantaged business in Cambridge, MA. The contract, which is a definitive, firm-fixed-price contract, supports SBIR Topic 314 and has an ultimate completion date of October 21, 2016. The contract is set aside for total small business participation.</p>
This $400,000 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Amplifidx Inc., a woman-owned small business. The contract supports the development of cancer prevention and diagnosis technologies for low-resource settings over a two-year period. This award aligns with NCI's mission to support innovative medical device research and development by small businesses. As a SBIR...